Search
moon
sun

T223. Type 1 DM

โ… . Introduction and epidemiology
* 5% ์ •๋„๊ฐ€ Type 1 DM์ด๋‹ค. โ…ก. Pathophysiology 1. T1DM (1) 'almost no circulating insulin' circulating ์ธ์А๋ฆฐ ๋ถ€์กฑ๊ณผ insulinogenic stimuli์— ๋ฐ˜์‘ํ•˜์ง€ ์•Š์€ ฮฒ-cell failure๋กœ ๋ฐœ์ƒ (2) ๋‹น๋‡จ ํ™˜์ž ์ค‘ 5~10%. : ์ฃผ๋กœ ์†Œ์•„, ์ Š์€ ์„ฑ์ธ. (peak age :ํ•™๋ น์ „, ์‚ฌ์ถ˜๊ธฐ). immune mediate case๊ฐ€ ๋Œ€๋ถ€๋ถ„ (3) ์น˜๋ฃŒํ•˜์ง€ ์•Š์œผ๋ฉด ๊ฑฐ์˜ ํ•ญ์ƒ spontaneous ketoacidosis๊ฐ€ ๋ฐœ์ƒํ•˜๋ฏ€๋กœ ์ƒ์กด์„ ์œ„ํ•˜์—ฌ ์ธ์А๋ฆฐ์ด ํ•„์ˆ˜. 2. ๊ณ ํ˜ˆ๋‹น์ด ๋ชจ๋“  type์˜ DM์—์„œ ๋‚˜ํƒ€๋‚˜๊ณ  ํ•ฉ๋ณ‘์ฆ์˜ ์ฃผ์š” ์š”์ธ์ด ๋˜๋ฏ€๋กœ euglycemic control์„ ์œ ์ง€ํ•˜๋Š” ๊ฒƒ์ด ์น˜๋ฃŒ์— ์ค‘์š”ํ•˜๋‹ค.
โ…ข. Diagnosis * ์•„๋ž˜ ์กฐ๊ฑด ์ค‘ ํ•˜๋‚˜๋งŒ ์ถฉ์กฑ๋˜๋ฉด ์ง„๋‹จํ•  ์ˆ˜ ์žˆ๋‹ค.
1. Prediabetes (1) Fasting plasma glucose 100~125mg/dL (5.6~7.0mmol/L) (2) HbA1C 5.7~6.4% (3) Oral glucose tolerance test์—์„œ 2hr plasma glucose 140~199mg/dL (7.8~11mmol/L) โ†’ preDM์œผ๋กœ ์ง„๋‹จ * HbA1c (1) RBC half-life ๋™์•ˆ ํ‰๊ท  blood glucose level์„ ๋ฐ˜์˜ (2) Thalassemia, anemia, CKD, chronic liver disease, pregnancy, heavy bleeding, 3๋‹ฌ ์ด๋‚ด ์ˆ˜ํ˜ˆ ๋ฐ›์€ ํ™˜์ž ๋“ฑ RBC turnover๊ฐ€ ์ฆ๊ฐ€ํ•ด์žˆ๋Š” ๊ฒฝ์šฐ ๋‹น๋‡จ ์ง„๋‹จ์— HbA1c assay๋ฅผ ์‚ฌ์šฉํ•˜๋Š” ๊ฒƒ์€ ์ •ํ™•ํ•˜์ง€ ์•Š๋‹ค. (3) ED์—์„œ๋Š” ์‹์‚ฌ์™€ ์ƒ๊ด€์—†์ด isolated hyperglycemia (casual plasma glucose)๋ฅผ ์ ‘ํ•˜๊ฒŒ ๋˜๋ฏ€๋กœ ๊ณ ํ˜ˆ๋‹น์˜ ์ฆ์ƒ์„ ๋ฌผ์–ด๋ณด๊ณ  ์ผ์ฐจ ์ง„๋ฃŒ์˜์—๊ฒŒ ๋ณด๋‚ธ๋‹ค.
โ…ฃ. Treatment 1. T1DM์€ ์ ˆ๋Œ€์ ์ธ ์ธ์А๋ฆฐ ๋ถ€์กฑ์ด ํŠน์ง•์ด๋ฏ€๋กœ ์ƒ์กด์„ ์œ„ํ•ด ์ธ์А๋ฆฐ์ด ํ•„์š”. 2. ์ธ์А๋ฆฐ์— ๋”ํ•ด ๊ธ€๋ฃจ์นด๊ณค ๋ถ„๋น„๋ฅผ ์–ต์ œํ•˜๊ธฐ ์œ„ํ•ด ์‹์‚ฌ ๋•Œ pramlintide (synthetic form of the ฮฒ-cell produced hormone amylin)์„ ํˆฌ์•ฝํ•œ๋‹ค. 3. ฮฒ-cell ์ด์‹, ์ทŒ์žฅ ์ด์‹, ์‹ /์ทŒ์žฅ ์ด์‹์ด ๋„์›€ ๋  ์ˆ˜ ์žˆ๋‹ค. โ…ค. Insulin 1. ์ตœ๊ทผ ์‚ฌ์šฉ๋˜๋Š” ์ธ์А๋ฆฐ์€ ๋ชจ๋‘ human type์œผ๋กœ ์‹ค์˜จ์—์„œ 30์ผ๊ฐ„ ๋ณด๊ด€ ๊ฐ€๋Šฅํ•˜๊ณ  100units/mL ๋†๋„๋กœ ํ‘œ์ค€ํ™”๋˜์–ด ์žˆ๋‹ค. (U100) high dose๊ฐ€ ํ•„์š”ํ•  ๋•Œ๋Š” regular insulin 500units/mL (U500)์„ ์‚ฌ์šฉํ•˜๊ธฐ๋„ ํ•œ๋‹ค.
2. Insulin analogues์™€ highly pure insulin preparation ์‚ฌ์šฉ์œผ๋กœ anti-insulin Ab ๋ฐœ์ƒ์ด ๊ฐ์†Œ๋˜์—ˆ๋‹ค. 3. ์ƒ๋ฆฌ์  ์ธ์А๋ฆฐ ์šฉ๋ฒ• (1) ์ผ์ผ ์š”๊ตฌ๋Ÿ‰์˜ ๋ฐ˜์„ basal insulin์œผ๋กœ ํˆฌ์•ฝ. (ํ•˜๋ฃจ 1๋ฒˆ long acting ๋˜๋Š” intermediate acting insulin์„ ํ•˜๋ฃจ ๋‘ ๋ฒˆ) (2) ์‹์ „ 5~30๋ถ„์— rapid-acting insulin ํˆฌ์•ฝ. ์‹์ „ ์ธ์А๋ฆฐ์€ ์†Œํ™”๋˜๋Š” ํƒ„์ˆ˜ํ™”๋ฌผ ์–‘ ๋”ฐ๋ผ ํˆฌ์—ฌ (insulin 1U for carbohydrate 15g, "carb counting") (3) ์ผ๋ถ€ ํ™˜์ž๋Š” ๋‹จ์ˆœํ™”ํ•˜์—ฌ ๋งค์‹์‚ฌ๋งˆ๋‹ค ์ •ํ•ด์ง„ ์šฉ๋Ÿ‰์„ ๋งž๋Š”๋‹ค.
4. ์ธ์А๋ฆฐ ํˆฌ์•ฝ๋ฒ• (1) Intermittent insulin dose โ‘  Syringe or pen์œผ๋กœ ์ œ๊ณต โ‘ก Syringe๊ฐ€ ๊ฐ€์žฅ ์ €๋ ดํ•˜์ง€๋งŒ ์ •ํ™•ํ•œ ์šฉ๋Ÿ‰ ํˆฌ์•ฝํ•˜๋Š”๋ฐ ์ฃผ์˜๊ฐ€ ํ•„์š”ํ•˜๋‹ค. โ‘ข ํŽœ์€ ๋ณด๋‹ค ์ •ํ™•ํ•˜๊ฒŒ ์ค„ ์ˆ˜ ์žˆ๋‹ค. (2) SC injection : m/c. โ‘  Regional circulatory ์ฐจ์ด๋กœ ์ธํ•˜์—ฌ ๋ถ€์œ„๋งˆ๋‹ค ํก์ˆ˜์œจ์ด ๋‹ค๋ฅด๋‹ค โ‘ก Single site์—์„œ๋งŒ ์‚ฌ์šฉ ์‹œ fibrosis or lipodystrophy ๋ฐœ์ƒ ๊ฐ€๋Šฅ. โ†’ ๊ทธ๋Ÿฌ๋ฏ€๋กœ ํ•œ ๋ถ€์œ„๋ฅผ ์ •ํ•ด์„œ region ์•ˆ์—์„œ ์—ฌ๋Ÿฌ site๋ฅผ ์‚ฌ์šฉํ•˜๋ผ๊ณ  ํ•ด์•ผ ํ•œ๋‹ค. (3) IV : plasma glucose์— ์ฆ‰๊ฐ์ ์ธ ํšจ๊ณผ๋ฅผ ์ฃผ๋ฏ€๋กœ ๊ณ ํ˜ˆ๋‹น ์œ„๊ธฐ (DKA, HHS)์—์„œ ๊ถŒ์žฅ๋จ.
โ…ฅ. Glycemic complications in insulin-dependent patients * ๊ณ ํ˜ˆ๋‹น์˜ ๊ธ‰์„ฑ ์ฆ์ƒ ์—†์ด ๋žฉ ์ด์ƒ์œผ๋กœ ์˜จ ๊ฒฝ์šฐ๋ฅผ ๋‹ค๋ฃฌ๋‹ค. 1. Hyperglycemia in previously diagnosed T1DM (1) T1DM ํ™˜์ž๊ฐ€ ๊ณ ํ˜ˆ๋‹น์œผ๋กœ ED์— ์ž์ฃผ ์˜ค๋ฉด ์‹์‚ฌ, ์ธ์А๋ฆฐ ํˆฌ์—ฌ๋Ÿ‰, ํ•˜๋ฃจ 4๋ฒˆ bst๋ฅผ ์ฒดํฌํ•ด ์˜ค๋ผ๊ณ  ํ•˜๊ณ  ์ธ์А๋ฆฐ ์šฉ๋Ÿ‰ ์กฐ์ ˆ์„ ์œ„ํ•ด ์ผ์ฐจ ์ง„๋ฃŒ์˜์—๊ฒŒ ๋ณด๋‚ด์•ผ ํ•œ๋‹ค. (4๋ฒˆ : ์•„์นจ์— ์ผ์–ด๋‚œ ํ›„, ์ ์‹ฌ์ „, ์ €๋…์ „, ์ทจ์นจ์ „) (2) ED์—์„œ ์ธ์А๋ฆฐ ์šฉ๋Ÿ‰์„ ์กฐ์ ˆํ•ด์•ผ ํ•˜๋ฉด ๊ธฐ๋ณธ์€ ํ•˜๋ฃจ 1~2๋ฒˆ long/intermediate acting insulin์„ ์ฃผ๊ณ  rapid acting insulin์„ ์‹์ „์— ์ค€๋‹ค. โ‘  Basal insulin ์–‘์„ ๋Š˜๋ฆฌ๋Š” ๊ฒƒ์€ ๊ณ ํ˜ˆ๋‹น ์ •๋„์— ๋”ฐ๋ผ ๋‹ค๋ฅด๋‹ค. โ‘ก ์ธ์А๋ฆฐ ์ด๋Ÿ‰์€ 0.2~0.4unit/kg/day์ด๊ณ  ๋ฐ˜์€ insulin glargine๊ฐ™์€ basal๋กœ ์ฃผ๊ณ  ๋ฐ˜์€ ์‹์ „์— ๋‚˜๋ˆ ์„œ ์ค€๋‹ค. โ‘ข ์ผ๋ฐ˜์ ์œผ๋กœ ์‹์ „์— ์ฃผ๋Š” rapid acting insulin์€ T1DM์—์„œ๋Š” 1unit์„ ํ˜ˆ๋‹น ๋ชฉํ‘œ ์ด์ƒ 50mg/dL ๋งˆ๋‹ค ์ฃผ๊ณ , T2DM์—์„œ๋Š” 30mg/dL ์ด์ƒ๋งˆ๋‹ค ์ค€๋‹ค. (3) ํ™˜์ž๊ฐ€ neutral protamine hagedorn insulin์„ ์‚ฌ์šฉํ•˜๋ฉด ์šฉ๊ธฐ๋ฅผ ํ™•์ธํ•œ๋‹ค. ๋ณ‘ ๋ฐ–์— ๊ฒฐ์ •์ด ๋ณด์ด๋ฉด
์†์ƒ๋œ ๊ฒƒ์œผ๋กœ ์ธ์А๋ฆฐ ํšจ๊ณผ๊ฐ€ ๋–จ์–ด์ ธ์„œ ๊ฐ€ ์ƒ๊ธธ ์ˆ˜ , (frosting) DKA ์žˆ์œผ๋ฏ€๋กœ ์ƒˆ๋กœ ์ฒ˜๋ฐฉํ•˜๊ณ  ์˜ˆ์ „ ๊ฒƒ์€ ๋ฒ„๋ ค์•ผ ํ•œ๋‹ค. * Falsely elevated capillary glucose (1) Icodextrin์„ ์‚ฌ์šฉํ•˜๋Š” ๋ณต๋ง‰ํˆฌ์„์•ก์€ ๋งŽ์€ point of care capillary glucose ์ฒดํฌ๋ฅผ ๋ฐฉํ•ดํ•œ๋‹ค. (2) False elevated reading์ด ์ƒ๊ธฐ๊ณ  ๊ทธ์— ๋”ฐ๋ผ ์ธ์А๋ฆฐ์„ ํˆฌ์•ฝํ•˜์—ฌ ์‹ฌํ•œ ์ €ํ˜ˆ๋‹น์ด ์˜ค๋Š” ๊ฒฝ์šฐ๊ฐ€ ์žˆ๋‹ค. (3) ๋ชจ๋“  ๋ณต๋ง‰ํˆฌ์„ ํ™˜์ž๋Š” central laboratory plasma glucose๋ฅผ ์ฒดํฌํ•ด์•ผ ํ•œ๋‹ค.
2. Hypoglycemia in insulin-dependent patients (1) ์ €ํ˜ˆ๋‹น (plasma glucose <70mg/dL)์€ intensive insulin therapy์˜ ํ•ฉ๋ณ‘์ฆ์œผ๋กœ ํ˜ˆ๋‹น tight control์˜ ์ฃผ์š” ๋ถ€์ž‘์šฉ์ด๋‹ค. โ‘  ์ธ์А๋ฆฐ ํˆฌ์•ฝ์— ์˜ํ•ด์„œ ๊ฐ€๋Šฅ โ‘ก T1DMํ™˜์ž๋Š” glucagon surge๊ฐ€ ์—†๊ณ  ์‹ ๊ฒฝ๋ณ‘์ฆ, ๋‚˜์ด, ์ด์ „ ์žฆ์€ ์ €ํ˜ˆ๋‹น ์ด๋ฒคํŠธ๋กœ ์ธํ•œ ์ž์œจ์‹ ๊ฒฝ๊ณ„ ์ด์ƒ ๋•Œ๋ฌธ์— ์—ํ”ผ๋„คํ”„๋ฆฐ ๋ถ„๋น„๊ฐ€ ์•ฝํ•˜์—ฌ ์ €ํ˜ˆ๋‹น์ด ์ƒ๊ธฐ๊ธฐ ์‰ฝ๋‹ค. (2) ์˜ค๋ž˜๋œ ์ธ์А๋ฆฐ ํˆฌ์—ฌ๋ฒ•์€ neutral protamine hagedorn์ด๋‚˜ lente insulin์„ basal insulin์œผ๋กœ ํ•˜๋ฃจ 1~2ํšŒ ํˆฌ์•ฝํ•˜๊ณ , ์‹์ „์— regular insulin์„ ํˆฌ์•ฝํ•˜๋Š” ๊ฒƒ์ด๋‹ค. ๋˜๋Š” premixed combination (70/30, 75/25, 50/50)์ด ์‚ฌ์šฉ๋˜๊ธฐ๋„ ํ•œ๋‹ค. โ‘  ์ด ์Šค์ผ€์ฅด์€ ์‹์‚ฌ ์‹œ๊ฐ„, ํ™œ๋™ ์Šค์ผ€์ฅด์— ๋”ฐ๋ผ ๊ณ ์ •๋˜๋ฏ€๋กœ ์‹์‚ฌ๋ฅผ ๋นผ๋จน๊ฑฐ๋‚˜ ์ผ์ƒ์ ์ด์ง€ ์•Š์€ ์ŠคํŠธ๋ ˆ์Šค ์ƒํ™ฉ์—์„œ๋Š” ์ €ํ˜ˆ๋‹น์ด ์ž˜ ์ƒ๊ธด๋‹ค. โ‘ก ํ˜„๋Œ€์˜ ์ƒ๋ฆฌ์ ์ธ ์ธ์А๋ฆฐ ํˆฌ์•ฝ๋ฒ•์€ ์ €ํ˜ˆ๋‹น์„ ๋งŽ์ด ์ค„์˜€์œผ๋‚˜ ๋งŽ์€ ํ™˜์ž๊ฐ€ ์ต์ˆ™ํ•จ, ๊ธˆ์ „์  ๋˜๋Š” ๋ณดํ—˜ ๋ฌธ์ œ ๋•Œ๋ฌธ์— premixed dosing์„ ์‚ฌ์šฉํ•˜๊ณ  ์žˆ๋‹ค. (3) ์ €ํ˜ˆ๋‹น์˜ ์›์ธ์„ ์ฐพ์•„์•ผ ํ•œ๋‹ค. โ‘  ํ”ํ•œ ์ด์œ ๋Š” ์Œ์‹์˜ ๋ถ€์กฑํ•œ ์„ญ์ทจ, ์ธ์А๋ฆฐ ๋ถ€์ •ํ™•ํ•œ ํˆฌ์•ฝ, ๊ฐ์—ผ, ์‹ ๊ธฐ๋Šฅ ์ด์ƒ, ACS, ์‹ฌํ•œ ์ •์‹ ์ / ์‹ ์ฒด์  ์ŠคํŠธ๋ ˆ์Šค ๋“ฑ์ด ์žˆ๋‹ค. โ‘ก ์‹์‚ฌ์— ์—ฐ๊ณ„ํ•˜์—ฌ ์ธ์А๋ฆฐ์˜ ํˆฌ์•ฝ๋Ÿ‰๊ณผ ์‹œ๊ฐ„์„ ํ™•์ธํ•œ๋‹ค. โ‘ข ์ €ํ˜ˆ๋‹น์˜ ์ฆ์ƒ์€ ํ™˜์ž๋งˆ๋‹ค ์ฐจ์ด๊ฐ€ ํฌ์ง€๋งŒ ๊ฐœ๋ณ„ ํ™˜์ž๋“ค์€ ๋งค๋ฒˆ ๋น„์Šทํ•œ ์ฆ์ƒ์„ ๋А๋‚€๋‹ค. (4) ์ฆ์ƒ โ‘  ํ”ํ•œ neuroglycopenic sx. : ์กธ๋ฆผ, ํ˜ผ๋ˆ, ์–ด์ง€๋Ÿฌ์›€, ํ”ผ๊ณคํ•จ, ์ง‘์ค‘ํ•  ์ˆ˜ ์—†์Œ, ๋งํ•˜๊ธฐ ์–ด๋ ค์›€ โ‘ก Adrenergic sx. : Tremor, ๋ฐœํ•œ, ๋ถˆ์•ˆ, ์˜ค์‹ฌ, ์‹ฌ๊ณ„ํ•ญ์ง„, feelings of warmth, ์˜คํ•œ โ‘ข ๊ธฐํƒ€ ์ฆ์ƒ : ๋ฐฐ๊ณ ํ””, ์œ„์•ฝ๊ฐ, Blurred vision
(5) ๋‹น๋‡จ ํ™˜์ž๊ฐ€ counter-regulatory ํ˜ธ๋ฅด๋ชฌ ๋ถ„๋น„๊ฐ€ ์—†์„ ๋•Œ hypoglycemic unawareness๋‚˜ hypoglycemia-associated autonomic failure๊ฐ€ ๋ฐœ์ƒํ•˜๋ฉด ์ €ํ˜ˆ๋‹น์˜ ์ฆ์ƒ์ด ์—†๋‹ค. โ‘  ์ด๋Š” ์ €ํ˜ˆ๋‹น์ด ์ž˜ ์ƒ๊ธฐ๊ณ  ์ €ํ˜ˆ๋‹น์ด ๋” ์‹ฌํ•˜๊ฒŒ ๋‚˜ํƒ€๋‚˜๊ฒŒ ํ•  ์ˆ˜ ์žˆ๋‹ค. โ‘ก ฮฒ-blocker๊ฐ€ ์ด ์ฆ์ƒ์„ ๋งŒ๋“ค ์ˆ˜ ์žˆ๊ณ , ์ „ํ˜•์ ์ธ ์ €ํ˜ˆ๋‹น์˜ sympathetic ์ฆ์ƒ์„ ๋งˆ์Šคํ‚นํ•  ์ˆ˜ ์žˆ๋‹ค.
(6) Treatment of Hypoglycemia ๊ฐ€ ์„ ํ˜ธ๋˜๋Š” ์น˜๋ฃŒ์ด๋‚˜ ์ด์™ธ์—๋„ ๋‹น์„ โ‘  Glucose , ํฌํ•จํ•œ ํƒ„์ˆ˜ํ™”๋ฌผ์„ ์‚ฌ์šฉํ•  ์ˆ˜ ์žˆ๋‹ค. โ‘ก ์ดˆ๊ธฐ ์šฉ๋Ÿ‰์€ 15~20g (PO, PR, IV)์ด๊ณ  15๋ถ„ ํ›„์—๋„ ์ €ํ˜ˆ๋‹น์ด ์ง€์†๋˜๋ฉด ๋ฐ˜๋ณตํ•ด์„œ ์‚ฌ์šฉํ•  ์ˆ˜ ์žˆ๋‹ค. โ‘ข Comatose ํ™˜์ž์—์„œ๋Š” IV, PR ๋ฃจํŠธ๊ฐ€ ํ•„์š”ํ•˜๋‹ค. โ‘ฃ Pure fructose๋Š” BBB๋ฅผ ํ†ต๊ณผํ•˜์ง€ ๋ชปํ•˜๊ณ , ๋‹จ๋ฐฑ์งˆ์€ serum glucose์— ๋ฏธ๋ฏธํ•œ ์˜ํ–ฅ์„ ์ฃผ๋ฏ€๋กœ ๋‘ ๊ฐ€์ง€๋Š” ์ €ํ˜ˆ๋‹น ์น˜๋ฃŒ์— ๋ถ€์ ํ•ฉํ•˜๋‹ค. โ‘ค Rectal syrup, ๊ฟ€์€ ํšจ๊ณผ์ ์ด๋‹ค. โ‘ฅ ์ €ํ˜ˆ๋‹น์ด ๋‚˜์•„์ง€๋ฉด ํ™˜์ž์—๊ฒŒ ์‹์‚ฌ๋‚˜ ํƒ„์ˆ˜ํ™”๋ฌผ ๊ณผ์ž๋ฅผ ๋จน๊ฒŒ ํ•œ๋‹ค. โ‘ฆ ๊ธ€๋ฃจ์นด๊ณค ์‘๊ธ‰ํ‚คํŠธ๋Š” T1DM ํ™˜์ž์˜ ๊ฐ€์กฑ, ๋ณดํ˜ธ์ž๊ฐ€ ๊ฐ€์ง€๊ณ  ์žˆ๋‹ค๊ฐ€ ์‚ฌ์šฉํ•  ์ˆ˜ ์žˆ๋‹ค. : 1mg IM glucagon์€ glycogenolysis๋ฅผ ์ด‰์ง„ํ•˜์—ฌ 10~15๋ถ„ ๋‚ด์— ํšจ๊ณผ์ ์ด๋‹ค. : ๊ธ€๋ฃจ์นด๊ณค์€ glycogen-depleted ํ™˜์ž์—์„œ๋Š” ํšจ๊ณผ์ ์ด์ง€ ์•Š๋‹ค. : ๊ธ€๋ฃจ์นด๊ณค์€ Nausea & Vomiting์„ ๋งŒ๋“ค์–ด ๊ฒฝ๊ตฌํฌ๋„๋‹น ๋ณต์šฉ์„ ์–ด๋ ต๊ฒŒ ํ•  ์ˆ˜ ์žˆ๋‹ค. โ‘ง ํ™˜์ž๊ฐ€ ์‚ผํ‚ฌ ์ˆ˜ ์žˆ์„๋งŒํผ alertํ•ด์ง€๋ฉด ๊ฒฝ๊ตฌ ํฌ๋„๋‹น์„ ๋ฐ”๋กœ ์ค€๋‹ค. โ‘จ Long-acting agent๋ฅผ ๋‹ค๋Ÿ‰ ๊ณผ๋ณต์šฉํ•œ ํ™˜์ž๋Š” ํ˜ˆ๋‹น ์ฒดํฌ๋ฅผ ์œ„ํ•ด ์ž…์›ํ•ด์•ผ ํ•œ๋‹ค. : ๋Œ€๋ถ€๋ถ„์˜ ํ™˜์ž๋Š” ๊ฐ€์กฑ๋“ค์ด ์ฆ์ƒ๊ณผ capillary glucose level์„ ์ž˜ ๋ณผ ์ˆ˜ ์žˆ์œผ๋ฉด ํ‡ด์›ํ•ด๋„ ๋œ๋‹ค. โ‘ฉ ํŽŒํ”„ ์‚ฌ์šฉ ํ™˜์ž์˜ ์ €ํ˜ˆ๋‹น : ๋˜‘๊ฐ™์ด ์น˜๋ฃŒํ•œ๋‹ค. : ํŽŒํ”„๋ฅผ ๋ถ„๋ฆฌํ•˜๋ฉด DKA๊ฐ€ ๋น ๋ฅด๊ฒŒ ์ƒ๊ธฐ๋ฏ€๋กœ ๋ถ„๋ฆฌํ•˜์ง€ ๋ง๋ผ. : ํŽŒํ”„ ์‚ฌ์šฉํ™˜์ž๊ฐ€ ๊ธˆ์‹ํ•ด์•ผ ํ•œ๋‹ค๋ฉด ํŽŒํ”„๋Š” ์ œ๊ฑฐํ•˜์ง€ ๋ง๊ณ  glucose level์„ 30~60๋ถ„๋งˆ๋‹ค ์ฒดํฌํ•ด์„œ ์ €ํ˜ˆ๋‹น์ด ์ƒ๊ธฐ๋ฉด ํŽŒํ”„ basal rate๋ฅผ ์ค„์ธ๋‹ค.
(7) Insulin overdose
โ…ฆ. Insulin pumps (continuous SC insulin infusion)
1.
๋ฏธ๊ตญ์—์„œ T1DM ํ™˜์ž์˜ 40%๊ฐ€ ์‚ฌ์šฉ.
2.
Subcutaneous catheter์— ์—ฐ๊ฒฐ๋œ flexible tube๋กœ rapid acting insulin์˜ ์ •ํ•ด์ง„ ์šฉ๋Ÿ‰์„ basal rate (๋ณดํ†ต 0.5~1.5unit/hr)๋กœ ๋ฐฐ์ถœํ•˜๊ณ  pump๋Š” ์˜ท์— ๋ถ€์ฐฉ. (ํŠœ๋ธŒ ์‚ฌ์šฉํ•˜์ง€ ์•Š๊ณ  ๋ฐ”๋กœ ๋ถ€์ฐฉ๋˜๋Š” ๊ฒƒ๋„ ์žˆ์Œ) (1) Reservoir๋Š” ์ˆ˜์ผ๋งˆ๋‹ค ํ•œ ๋ฒˆ์”ฉ ๋ณด์ถฉํ•˜๊ณ , catheter๋Š” 3์ผ๋งˆ๋‹ค ๊ตํ™˜. (2) Basal rate๋Š” ํ•˜๋ฃจ ์ค‘ ์กฐ์ ˆ ๊ฐ€๋Šฅ. (์ด๋ฅธ ์•„์นจ cortisol surge ๋•Œ ์ฆ๋Ÿ‰, ์šด๋™ ์ „์—๋Š” ๊ฐ๋Ÿ‰.) (3) Continuous basal insulin ํˆฌ์•ฝ ํ†ตํ•ด long acting insulin์„ ๋Œ€์ฒดํ•˜์—ฌ rapid acting insulin์œผ๋กœ๋งŒ ํˆฌ์•ฝ ๊ฐ€๋Šฅํ•ด์ง. (4) ์˜ˆ์™ธ์ ์œผ๋กœ high dose insulin์„ ํ•„์š”๋กœ ํ•˜๋Š” ๊ฒฝ์šฐ๋‚˜ ์ผ์ • ์‹œ๊ฐ„ pump๋ฅผ ๋–ผ๊ณ  ์‹ถ์€ ๊ฒฝ์šฐ, ๊ณ ํ˜ˆ๋‹น์ด๋‚˜ DKA์œ„ํ—˜์ด ๋†’์€ ๊ฒฝ์šฐ (young children) ํ•˜๋ฃจ 1-2๋ฒˆ long acting insulin์„ ํˆฌ์•ฝํ•˜๊ธฐ๋„ ํ•จ. (5) ํŽŒํ”„๋Š” ๊ณ ํ˜ˆ๋‹น ๋•Œ๋‚˜ ์‹์ „์— ์ˆ˜๋™ bolus ํˆฌ์•ฝ ๊ฐ€๋Šฅ. (6) ํŽŒํ”„๋Š” DM, ํƒ„์ˆ˜ํ™”๋ฌผ counting ๊ต์œก์„ ์ž˜ ๋ฐ›์•˜๊ณ , ํ•˜๋ฃจ 4~6๋ฒˆ capillary glucose๋ฅผ ์ฒดํฌํ•  ์ˆ˜ ์žˆ๋Š”, ์˜์š•์žˆ๋Š” ํ™˜์ž์—๊ฒŒ ์œ ์šฉ.
3.
์–ด๋–ค ๋ชจ๋ธ์€ continuous glucose monitoring์ด ๊ฐ€๋Šฅ. (1) Capillary glucose monitoring์— ๋ถ€ํ•ฉํ•˜๋Š” interstitial glucose concentration์„ ์ฒดํฌํ•ด์„œ ๋ณด์—ฌ์ค„ ์ˆ˜ ์žˆ๋‹ค. (2) Interstitial glucose๋Š” serum glucose๋ฅผ ๋Œ€์ฒดํ•ด์„œ, absolute glucose level๋ณด๋‹ค ํŠธ๋ Œ๋“œ๋ฅผ ๋ชจ๋‹ˆํ„ฐ๋ง ํ•˜๊ธฐ์— ์ข‹๋‹ค. (3) ED์—์„œ๋Š” capillary or serum glucose level์„ ๋ชจ๋‹ˆํ„ฐํ•ด์•ผํ•˜๊ณ , interstitial glucose value๋Š” ์ง„๋‹จ ๋ชฉ์ ์œผ๋กœ ์‚ฌ์šฉํ•  ์ˆ˜ ์—†๋‹ค.
4. ์ธ์А๋ฆฐ ํŽŒํ”„ ํ•ฉ๋ณ‘์ฆ (1) Disconnection, empty reservoir, kinked catheter, priming error ๋“ฑ์œผ๋กœ ๋ฌธ์ œ ๋ฐœ์ƒ ๊ฐ€๋Šฅ. (2) ํŽŒํ”„๋Š” rapid acting insulin๋งŒ ์‚ฌ์šฉํ•˜๋ฏ€๋กœ ํŽŒํ”„๊ฐ€ ๊ณ ์žฅ๋‚˜๋ฉด ketoacidosis๊ฐ€ ๋งค์šฐ ๋น ๋ฅด๊ฒŒ ๋ฐœ์ƒํ•œ๋‹ค. (1์‹œ๊ฐ„ ์ด๋‚ด) (3) ๋งŒ์•ฝ ํŽŒํ”„๊ฐ€ ๋ฌธ์ œ๊ฐ€ ์žˆ๊ฑฐ๋‚˜ MRI ๋“ฑ์œผ๋กœ ์ œ๊ฑฐ๋˜์–ด์•ผ ํ•˜๋Š” ๋“ฑ ํŽŒํ”„๊ฐ€ 1์‹œ๊ฐ„ ์ด์ƒ ํˆฌ์•ฝ๋˜์ง€ ์•Š๋Š” ๊ฒฝ์šฐ์— ํ™˜์ž์—๊ฒŒ rapid acting insulin์ด๋‚˜ long acting insulin์„ ์ค˜์•ผ ํ•œ๋‹ค. (4) ํ™˜์ž๊ฐ€ insulin์„ multiple injection์œผ๋กœ ๋งž๋‹ค๊ฐ€ pump๋กœ ๊ต์ฒดํ•˜๊ณ  ์žˆ์„ ๋•Œ ED์— ์˜ค๋ฉด ๊ณ ํ˜ˆ๋‹น, ์ €ํ˜ˆ๋‹น์„ ํŠนํžˆ ์ฃผ์˜ํ•ด์„œ ๋ด์•ผ ํ•˜๊ณ , ํŽŒํ”„ infusion site์˜ cellulitis, lipodystrophy์— ์œ ์˜ํ•ด์•ผ ํ•œ๋‹ค. 5. ์ธ์А๋ฆฐํŽŒํ”„ ์‚ฌ์šฉํ•˜๋Š” ๊ฒฝ์šฐ * ๊ณ ํ˜ˆ๋‹น/์ €ํ˜ˆ๋‹น์œผ๋กœ ์˜ค๋ฉด ์ •ํ•ด์ง„ ๊ฐ€์ด๋“œ๋ผ์ธ์€ ์—†๊ณ  multiple daily dose ์ธ์А๋ฆฐ ์‚ฌ์šฉํ•˜๋Š” ์‚ฌ๋žŒ๊ณผ ๊ฐ™์ด ์น˜๋ฃŒํ•˜๊ณ  ํŽŒํ”„๊ฐ€ ๊ณ ์žฅ๋‚˜์ง€ ์•Š๋„๋ก ์œ ์˜. (1) ํŽŒํ”„ ์‚ฌ์šฉํ•˜๋Š” ํ™˜์ž์—์„œ ๊ณ ํ˜ˆ๋‹น โ‘  ๊ณ ํ˜ˆ๋‹น์—์„œ๋Š” ํŽŒํ”„๋กœ rapid-acting SC insulin bolus๋ฅผ ์ค€๋‹ค. โ‘ก ํ™˜์ž๊ฐ€ ์•ˆ์ •ํ™”๋˜๋ฉด ๋ฌด๋ถ„๋ณ„ํ•œ ์‹์ด, ๊ฐ์—ผ ์—ฌ๋ถ€ ๋“ฑ์„ ์ฐพ๊ณ , ์ธ์А๋ฆฐ ํŽŒํ”„์— ๋Œ€ํ•ด ๋ฌผ์–ด๋ณธ๋‹ค. (Reservoir๋ฅผ ์–ธ์ œ ์ฑ„์› ๋‚˜, infusion set๋ฅผ ๋งˆ์ง€๋ง‰์œผ๋กœ ๊ต์ฒดํ•œ ๋•Œ๋Š” ์–ธ์ œ์ธ๊ฐ€, insertion site๋Š” ์ฃผ๊ธฐ์  ์œผ๋กœ ๋ฐ”๊ฟจ๋‚˜, ํŽŒํ”„๊ฐ€ ์ผœ์ ธ ์žˆ๋‚˜, reservoir๊ฐ€ ๋นˆ ๊ฑด ์•„๋‹Œ๊ฐ€, ์•Œ๋žŒ์€ ์šธ๋ฆฌ๊ฒŒ ๋˜์–ด ์žˆ๋‚˜, tube๊ฐ€ ๊ผฌ์ด์ง„
์•Š์•˜๋‚˜, infusion site๋Š” ํ”ผ๋ถ€์— ์ž˜ ๋ถ™์–ด์žˆ๋‚˜.) โ‘ข ํŽŒํ”„ ์‚ฌ์šฉ์— ๋Œ€ํ•ด ์ž˜ ์•Œ๋ ค์ฃผ๊ณ  24์‹œ๊ฐ„ ๊ธฐ์ˆ ์ง€์›๋ฒˆํ˜ธ๋ฅผ ์•Œ๋ ค์ค€๋‹ค. โ‘ฃ ํŽŒํ”„ ์ด์ƒ์ด ์˜์‹ฌ๋˜๋ฉด ๋‚ด๋ถ„๋น„๋‚ด๊ณผ์— ํŽŒํ”„๋ฅผ long-acting basal insulin์œผ๋กœ ๊ต์ฒดํ•  ๊ฒƒ์„ ์š”์ฒญํ•œ๋‹ค. (2) ํŽŒํ”„ ์‚ฌ์šฉํ•˜๋Š” ํ™˜์ž์—์„œ DKA โ‘  ํŽŒํ”„์˜ ๋ฌธ์ œ๋ฅผ ์ถ”์ •ํ•˜๊ณ  ํŽŒํ”„๋ฅผ ๋ถ„๋ฆฌํ•˜๊ณ  IV ์ธ์А๋ฆฐ ํˆฌ์•ฝ๊ณผ DKA ์น˜๋ฃŒ ํ”„๋กœํ† ์ฝœ์„ ์‹œ์ž‘ํ•œ๋‹ค. โ‘ก DKA๊ฐ€ ํ•ด๊ฒฐ๋˜๋ฉด IV ์ธ์А๋ฆฐ ๋ฉˆ์ถ”๊ธฐ 1์‹œ๊ฐ„ ์ „์— long acting insulin์„ ํˆฌ์•ฝํ•˜๊ฑฐ๋‚˜ ํŽŒํ”„๋ฅผ ์žฌ์‹œ์ž‘ โ‘ข ํŽŒํ”„ ์น˜๋ฃŒ๋ฅผ ์žฌ์‹œ์ž‘ํ•˜๋ ค๋ฉด ํŽŒํ”„๊ฐ€ ์ž˜ ์ž‘๋™ํ•˜๋Š”์ง€ ๊ธฐ๊ณ„๋ฅผ ์ฒดํฌํ•˜๊ณ , ์ƒˆ๋กœ์šด ์ธ์А๋ฆฐ์œผ๋กœ reservoir๋ฅผ ์ฑ„์šฐ๊ณ  ์ƒˆ SC ์ธ์А๋ฆฐ ์นดํ…Œํ„ฐ๋ฅผ ๋„ฃ๋Š”๋‹ค. โ‘ฃ 30~60๋ถ„๋งˆ๋‹ค serum glucose level์„ ์ฒดํฌํ•œ๋‹ค. (3) ํŽŒํ”„ ์‚ฌ์šฉํ•˜๋Š” ํ™˜์ž์—์„œ ์ €ํ˜ˆ๋‹น : DKA๊ฐ€ ๋น ๋ฅด๊ฒŒ ์ง„ํ–‰ํ•  ์ˆ˜ ์žˆ๊ธฐ ๋•Œ๋ฌธ์—, ์ €ํ˜ˆ๋‹น์ด๋”๋ผ๋„ ์ธ์А๋ฆฐํŽŒํ”„๋ฅผ ์ค‘๋‹จํ•ด์„œ๋Š” ์•ˆ๋œ๋‹ค. (4) ์‘๊ธ‰์‹ค์— ๋‹น๋‡จ ๋ฌธ์ œ ์ด์™ธ๋กœ ๋‚ด์›ํ–ˆ๋‹ค๊ฐ€ ์šฐ์—ฐํžˆ ๊ณ ํ˜ˆ๋‹น์ด๋‚˜ ์ €ํ˜ˆ๋‹น์ด ๋ฐœ๊ฒฌ๋œ ๊ฒฝ์šฐ์—๋Š” ํ™˜์ž ์Šค์Šค๋กœ ๊ต์œก ๋ฐ›์€๋Œ€๋กœ ๋Œ€์ฒ˜ํ•˜๊ฒŒ ํ•ด์ค˜์•ผ ํ•œ๋‹ค. (์ €ํ˜ˆ๋‹น์—” ๋‹น์„ญ์ทจ, ๊ณ ํ˜ˆ๋‹น์— ์ธ์А๋ฆฐ bolus ์ฃผ์ž… ๋“ฑ)
โ…ง. Special considerations 1. Undiagnosed diabetic (1) T2DM์€ ์ฆ์ƒ ์—†์ด ์˜ค๋žœ ์‹œ๊ฐ„ ๋ณด๋‚ด๋Š” ๊ฒฝ์šฐ๊ฐ€ ๋งŽ์œผ๋‚˜ T1DM์€ ์ผ๋ฐ˜์ ์œผ๋กœ ๋ฐœ๋ณ‘ ์ „์— ์งง์€ ์ฆ์ƒ ๊ธฐ๊ฐ„์„ ๊ฐ€์ง„๋‹ค. (2) ํ™˜์ž๊ฐ€ ์ƒˆ๋กœ ๋ฐœ๊ฒฌ๋œ ์‹ฌํ•œ ์ฆ์ƒ์ด ์žˆ๋Š” ๊ณ ํ˜ˆ๋‹น (glucose >250~300mg/dL or 13.8~16.7mmol/L)์„ ๋ณด์ด๋ฉด ์‘๊ธ‰์‹ค์—์„œ ์ธ์А๋ฆฐ์ด ํˆฌ์•ฝ๋˜์–ด์•ผ ํ•œ๋‹ค. โ‘  ์ธ์А๋ฆฐ์€ ํ™˜์ž๊ฐ€ T1 or T2 DM์ธ์ง€ ๋ชจ๋ฅผ ๋•Œ์—๋„ ํˆฌ์•ฝ๋  ์ˆ˜ ์žˆ๋‹ค. โ‘ก ์‹ฌํ•œ ๊ณ ํ˜ˆ๋‹น ์ฆ์ƒ์ด ์žˆ๋Š” ํ™˜์ž๋Š” ์ธ์А๋ฆฐ ํˆฌ์•ฝ ํ›„ observation unit์— ์ž…์›ํ•˜์—ฌ ๋‹น์กฐ์ ˆ ๋ฐ ๊ต์œก์„ ๋ฐ›์•„์•ผ ํ•œ๋‹ค. โ‘ข ๋‚ฎ์€ ์šฉ๋Ÿ‰์˜ regular or rapid-acting insulin (ํ˜ˆ๋‹น์ด 250~300mg/dL์ด์ƒ์ผ ๋•Œ 1 unit SC for every 30mg/dL above glucose 250~300mg/dL)์ด ๊ณ ํ˜ˆ๋‹น์„ ๋‚ฎ์ถ”๊ธฐ ์œ„ํ•ด ํˆฌ์•ฝ๋˜๊ณ , DKA๋ฅผ ์˜ˆ๋ฐฉํ•˜๊ธฐ ์œ„ํ•ด ์œ„ํ•ด long acting insulin (0.1-0.2unit/kg of insulin glargine)์ด ํˆฌ์•ฝ๋œ๋‹ค. โ‘ฃ ์‹ฌํ•œ ๊ณ ํ˜ˆ๋‹น ์ฆ์ƒ์ด ์—†๋Š” ํ™˜์ž๋“ค์€ ํ˜ˆ๋‹น์„ 250mg/dL ์ดํ•˜๋กœ ๋‚ฎ์ถ”๊ธฐ ์œ„ํ•ด regular or rapid acting insulin์ด ํˆฌ์•ฝ๋œ๋‹ค. โ‘ค ์‘๊ธ‰์‹ค์—์„œ normoglycemia๊ฐ€ ๋  ํ•„์š”๋Š” ์—†๋‹ค. โ‘ฅ ํ™˜์ž๋Š” metformin์„ ์ฒ˜๋ฐฉํ•˜์—ฌ ํ‡ด์›ํ•  ์ˆ˜ ์žˆ๊ณ  ํ–ฅํ›„ ์น˜๋ฃŒ๋ฅผ ์œ„ํ•ด 24์‹œ๊ฐ„ ์ด๋‚ด์— ์ผ์ฐจ ์ง„๋ฃŒ์˜์—๊ฒŒ ๋ณด๋‚ด๋ฉด ๋œ๋‹ค.
2. Glucocorticoid therapy (1) DM์˜ other specific type์ด๋ผ๊ณ ๋„ ํ•œ๋‹ค. (2) Glucocorticoid๋ฅผ ํˆฌ์•ฝํ•˜๋Š” ํ™˜์ž๋Š” DKA๋‚˜ HHS์™€ ๊ฐ™์€ ๊ณ ํ˜ˆ๋‹น ์œ„๊ธฐ๊ฐ€ ๋ฐœ์ƒํ•  ์œ„ํ—˜์ด ์žˆ๋‹ค. (3) ED ํ‡ด์› ์ „์— glucocorticoid๋ฅผ ์‹œ์ž‘ํ•œ T1DM ํ™˜์ž๋Š” ๊ณ ํ˜ˆ๋‹น์ด ๋ฐœ์ƒํ•  ๊ฐ€๋Šฅ์„ฑ์ด ํฌ๋ฏ€๋กœ ๊ณ ํ˜ˆ๋‹น ์œ„ํ—˜ ์ฆ์ƒ์— ๋Œ€ํ•ด ๊ฒฝ๊ณ ํ•˜๊ณ  ์ง‘์—์„œ ์•„์นจ๋งˆ๋‹ค ์ž์ฃผ ํ˜ˆ๋‹น์„ ์žฌ๊ณ  ์ถ”๊ฐ€์ ์œผ๋กœ ์‹์ „ ์ธ์А๋ฆฐ์„ ํˆฌ์•ฝํ•˜๋ฉฐ ์ผ์ฐจ ์ง„๋ฃŒ ์˜์—๊ฒŒ close f/u ํ•˜๋„๋ก ํ•ด์•ผ ํ•œ๋‹ค. ๋ฃจํ‹ด์œผ๋กœ basal insulin dose๋ฅผ ์˜ฌ๋ฆฌ์ง€๋Š” ์•Š๋Š”๋‹ค.
๊ธฐ์กด์— ์ง„๋‹จ๋ฐ›์ง€ ์•Š์€ ๋‹น๋‡จ๊ฐ€ ์น˜๋ฃŒ ๋™์•ˆ ๊ณ ํ˜ˆ๋‹น์ด (4) glucocorticoid ๋ฐœ์ƒํ•  ์ˆ˜ ์žˆ์œผ๋‚˜ ๊ณ ํ˜ˆ๋‹น์€ ๋ณดํ†ต glucocorticoid ์น˜๋ฃŒ๊ฐ€ ์™„๋ฃŒ๋˜๋ฉด ์ €์ ˆ๋กœ ํ˜ธ์ „๋œ๋‹ค. (5) ๋งŒ์•ฝ ๊ณ ํ˜ˆ๋‹น์ด ์ง€์†๋˜๊ฑฐ๋‚˜ ์ฆ์ƒ์ด ์ƒ๊ธฐ๋ฉด ์‹์ด ์กฐ์ ˆ์ด๋‚˜ ์šด๋™ ์น˜๋ฃŒ๋ฅผ ํ•ด ๋ณด๊ณ , ํ˜ธ์ „์ด ์—†๋‹ค๋ฉด ํˆฌ์•ฝ์ด ํ•„์š”ํ•˜๋‹ค.
3. Pramlintide (1) ์ธ์А๋ฆฐ์œผ๋กœ glucose control์ด ์•ˆ ๋˜๋Š” T1DM ํ™˜์ž๋Š” ์‹์ „ ์ธ์А๋ฆฐ์— ฮฒ cell์—์„œ ์ƒ์„ฑ๋˜๋Š” amylin hormone์˜ ํ•ฉ์„ฑ์ œ์ œ์ธ pramlintide์„ ์‹์‚ฌ ๋•Œ ์ถ”๊ฐ€๋กœ ์‚ฌ์šฉ ๊ฐ€๋Šฅ. (2) Amylin : ํฌ๋งŒ๊ฐ์„ ์ด‰์ง„ํ•˜๊ณ , gastric emptying์„ ์ฒœ์ฒœํžˆ ๋˜๊ฒŒ ํ•˜๊ณ  glucagon secretion์„ ์–ต์ œํ•˜์—ฌ HbA1c ๋ ˆ๋ฒจ์„ ๋‚ฎ์ถ˜๋‹ค. (3) ์ธ์А๋ฆฐ ์šฉ๋Ÿ‰์„ ๋‚ฎ์ถ”์ง€ ์•Š๊ณ  pramlintide ์น˜๋ฃŒ ์‹œ์ž‘ํ•˜๋ฉด ์ฒซ 4์ฃผ์— ์‹ฌํ•œ hypoglycemia์˜ ๋ฐœ์ƒ์ด ์ฆ๊ฐ€ ํ•  ์ˆ˜ ์žˆ์–ด ์œ ์˜ํ•ด์•ผ ํ•˜๋ฉฐ, hypoglycemia ์œ„ํ—˜์„ ๋ง‰๊ธฐ ์œ„ํ•ด pramlintide๋ฅผ ์‹œ์ž‘ํ•˜๋ฉด ์ธ์А๋ฆฐ์€ 25% ๊ฐ๋Ÿ‰ํ•ด์•ผ ํ•œ๋‹ค. 4. Transplantion (1) ์ทŒ์žฅ ์ด์‹์˜ 3๊ฐ€์ง€ ๋ฐฉ๋ฒ• : ์ทŒ์žฅ/์‹ ์žฅ ๋™์‹œ ์ด์‹, ์‹ ์ด์‹ ํ›„ ์ทŒ์žฅ์ด์‹, ์ทŒ์žฅ๋งŒ ์ด์‹ (2) Sirolomus, tacrolimus ๋“ฑ์œผ๋กœ ์˜ค๋žœ ์‹œ๊ฐ„ ๋ฉด์—ญ ์–ต์ œ๋ฅผ ํ•ด์•ผ ํ•œ๋‹ค. (3) Islet cell ์ด์‹ โ‘  Edmonton protocol์ด ์„ฑ๊ณต์ ์ธ ๋ฐฉ๋ฒ• ์ค‘ ํ•˜๋‚˜ โ‘ก T1DM์—์„œ insulin independence๋ฅผ ๋งŒ๋“ค ์ˆ˜ ์žˆ๋‹ค. โ‘ข ๊ทธ๋Ÿฌ๋‚˜ ๊ธฐ๊ฐ„์ด ์งง์•„์„œ 2๋…„ ๋’ค์—๋Š” 76%์˜ ํ™˜์ž๊ฐ€ ๋‹ค์‹œ ์ธ์А๋ฆฐ์ด ํ•„์š”ํ•ด์ง„๋‹ค *
* โ€˜Dead in bedโ€™ syndrome (1) Uncomplicated T1DM ์ Š์€ ์„ฑ์ธ์ด ๊ฑด๊ฐ•ํžˆ ์ž ๋“ค์—ˆ๋‹ค๊ฐ€ ๊ฐ‘์ž๊ธฐ ์ฃฝ๋Š” ํ˜„์ƒ์ด๋‹ค. (์นจ๋Œ€์—๋Š” ๊ดด๋กœ์›Œํ•˜๊ฑฐ๋‚˜ ๊ฒฝ๋ จํ•œ ํ”์  ์—†์Œ) (2) ๋ถ€๊ฒ€ํ•ด๋ณด๋ฉด ํ™˜์ž๋“ค์€ ์ €ํ˜ˆ๋‹น ์ƒํƒœ์ด๋‚˜ ๋‹ค๋ฅธ ๋ณ‘๋ฆฌ์  ์†Œ๊ฒฌ์€ ์—†๋‹ค. (3) ์ง„๋‹จ๋˜์ง€ ์•Š์€ autonomic neuropathy๋กœ ๋” ์•…ํ™”๋œ ์ €ํ˜ˆ๋‹น์ด QT prolongation์„ ๋งŒ๋“ค์–ด ๋ถ€์ •๋งฅ ์œ ๋ฐœํ•œ๋‹ค๋Š” ๊ฐ€์„ค์ด ์žˆ๋‹ค. (4) T1DM ์ Š์€ ํ™˜์ž์˜ ์ €ํ˜ˆ๋‹น์—๋Š” ํŠนํžˆ ์œ ์˜.